{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:35:12Z","timestamp":1785785712941,"version":"3.56.0"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,9]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Autologous stem cell transplantation (ASCT<\/jats:styled-content>) following BEAM<\/jats:styled-content> (BCNU<\/jats:styled-content>, etoposide, cytarabine, melphalan) conditioning is standard of care in relapsed low\u2010 and high\u2010grade B\u2010cell lymphoma (DLBCL<\/jats:styled-content>) and other lymphoproliferative disorders, but BCNU<\/jats:styled-content> is associated with interstitial pneumonia and an increased mortality. A less toxic regimen might improve the outcome of patients with lymphoma after transplantation.<\/jats:p><\/jats:sec>Objectives<\/jats:title>We investigated the role of bendamustine replacing BCNU<\/jats:styled-content> in the BEAM<\/jats:styled-content> regimen in patients with lymphoma undergoing ASCT<\/jats:styled-content>.<\/jats:p><\/jats:sec>Patients\/Methods<\/jats:title>The conditioning regimen BendaEAM<\/jats:styled-content> consisted of bendamustine, cytarabine, etoposide, and melphalan and was used in patients with Hodgkin\u2032s disease (HD<\/jats:styled-content>) and Non\u2010Hodgkin lymphoma (NHL<\/jats:styled-content>).<\/jats:p><\/jats:sec>Results<\/jats:title>Forty\u2010one patients with HD<\/jats:styled-content> (n\u00a0=\u00a09) or NHL<\/jats:styled-content> (n\u00a0=\u00a032) were consecutively treated with Benda\u2010BEAM<\/jats:styled-content> replacing BCNU<\/jats:styled-content>. No pulmonary or renal toxicities occurred, and no patient died related to transplant. After a median follow\u2010up of 55\u00a0months, CR<\/jats:styled-content> rate was 56%, 18 patients (44%) showed progression after a median time of 7\u00a0months after transplantation (range: 2\u201029\u00a0months), and 11 patients (24%) have died, all due to lymphoma progression. The 1\u2010, 2\u2010, and 4\u2010year PFS<\/jats:styled-content> are 73.2%, 58.6%, and 55.6% and the 1\u2010, 2\u2010, and 4\u2010year OS<\/jats:styled-content> 85.4%, 78.0%, and 72.6%, respectively.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>BendaEAM<\/jats:styled-content> seems to be feasible with a promising response rate and acceptable toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13102","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T15:14:18Z","timestamp":1527261258000},"page":"326-331","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["High\u2010dose Bendamustine\u2010EAM<\/scp> followed by autologous stem cell rescue results in long\u2010term remission rates in lymphoma patients, without renal toxicity"],"prefix":"10.1111","volume":"101","author":[{"given":"Thomas","family":"Noesslinger","sequence":"first","affiliation":[{"name":"Third Medical Department for Hematology and Oncology Hanusch Krankenhaus Wien Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Panny","sequence":"additional","affiliation":[{"name":"Third Medical Department for Hematology and Oncology Hanusch Krankenhaus Wien Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Simanek","sequence":"additional","affiliation":[{"name":"Third Medical Department for Hematology and Oncology Hanusch Krankenhaus Wien Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Moestl","sequence":"additional","affiliation":[{"name":"Third Medical Department for Hematology and Oncology Hanusch Krankenhaus Wien Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Boehm","sequence":"additional","affiliation":[{"name":"Third Medical Department for Hematology and Oncology Hanusch Krankenhaus Wien Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Menschel","sequence":"additional","affiliation":[{"name":"Third Medical Department for Hematology and Oncology Hanusch Krankenhaus Wien Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Koller","sequence":"additional","affiliation":[{"name":"Third Medical Department for Hematology and Oncology Hanusch Krankenhaus Wien Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-1677","authenticated-orcid":false,"given":"Felix","family":"Keil","sequence":"additional","affiliation":[{"name":"Third Medical Department for Hematology and Oncology Hanusch Krankenhaus Wien Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_5_4_1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.V122.21.2127.2127","article-title":"Safety and efficacy Of Lomustine (CCNU) substituting Carmustine (BCNU) in conditioning for autologous haematopoietic stem cell transplantation in lymphoma. a retrospective analysis of two patient cohorts over a ten year period","volume":"122","author":"Sommerfeld SA","year":"2013","journal-title":"Blood"},{"issue":"4","key":"e_1_2_5_5_1","first-page":"12","article-title":"In vitro studies with bendamustine: enhanced activity in combination with rituximab","volume":"29","author":"Rummel MJ","year":"2002","journal-title":"SeminOncol"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01994.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351924"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.688200"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2011.09.007"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_15_1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1182\/blood.V124.21.430.430","article-title":"Do changes in transplant practice influence risk of therapy\u2010related myelodysplasia\/acute myeloid leukemia after autologous Hematopoietic Cell Transplantation (aHCT) for Non\u2010Hodgkin Lymphoma (NHL)?","volume":"124","author":"Sun CL","year":"2014","journal-title":"Blood"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-90-2-191"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.107.2.482"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0035"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2900-y"},{"key":"e_1_2_5_20_1","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood.V128.22.3450.3450","article-title":"Bendamustine\u2010based (BeEAM) conditioning before autologous stem cell transplantation: result of a French multicenter study of 386 patients from Lysa centers","volume":"128","author":"Chantepie S","year":"2016","journal-title":"Blood"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.257"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.06.014"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1403019"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701790"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T16:04:00Z","timestamp":1694966640000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/ejh.13102"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13102","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"assertion":[{"value":"2018-05-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}